Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's disease.
cholinergic system
cognitive decline
free-water imaging
nucleus basalis of Meynert
pedunculopontine nucleus
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
15
10
2021
revised:
22
02
2022
accepted:
25
02
2022
pubmed:
30
4
2022
medline:
4
3
2023
entrez:
29
4
2022
Statut:
ppublish
Résumé
Free-water imaging can predict and monitor dopamine system degeneration in people with Parkinson's disease. It can also enhance the sensitivity of traditional diffusion tensor imaging (DTI) metrics for indexing neurodegeneration. However, these tools are yet to be applied to investigate cholinergic system degeneration in Parkinson's disease, which involves both the pedunculopontine nucleus and cholinergic basal forebrain. Free-water imaging, free-water-corrected DTI and volumetry were used to extract structural metrics from the cholinergic basal forebrain and pedunculopontine nucleus in 99 people with Parkinson's disease and 46 age-matched controls. Cognitive ability was tracked over 4.5 years. Pearson's partial correlations revealed that free-water-corrected DTI metrics in the pedunculopontine nucleus were associated with performance on cognitive tasks that required participants to make rapid choices (behavioural flexibility). Volumetric, free-water content and DTI metrics in the cholinergic basal forebrain were elevated in a sub-group of people with Parkinson's disease with evidence of cognitive impairment, and linear mixed modelling revealed that these metrics were differently associated with current and future changes to cognition. Free water and free-water-corrected DTI can index cholinergic degeneration that could enable stratification of patients in clinical trials of cholinergic interventions for cognitive decline. In addition, degeneration of the pedunculopontine nucleus impairs behavioural flexibility in Parkinson's disease, which may explain this region's role in increased risk of falls.
Identifiants
pubmed: 35485491
pii: 6575811
doi: 10.1093/brain/awac127
pmc: PMC9976974
doi:
Substances chimiques
Cholinergic Agents
0
Water
059QF0KO0R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1053-1064Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Neurobiol Aging. 2015 Feb;36(2):1097-104
pubmed: 25467638
Psychopharmacology (Berl). 2020 Jan;237(1):137-153
pubmed: 31620809
J Neurol Neurosurg Psychiatry. 1985 May;48(5):413-21
pubmed: 3998751
Neuroscience. 1983 Dec;10(4):1185-201
pubmed: 6320048
Neural Regen Res. 2020 Sep;15(9):1590-1600
pubmed: 32209758
J Neural Transm (Vienna). 2018 Mar;125(3):471-483
pubmed: 28084536
Parkinsonism Relat Disord. 2019 Aug;65:146-152
pubmed: 31182373
Brain. 2018 Jan 1;141(1):165-176
pubmed: 29228203
J Alzheimers Dis. 2014;40(3):687-700
pubmed: 24503619
Mov Disord. 2021 Mar;36(3):611-621
pubmed: 33382126
Brain. 2015 May;138(Pt 5):1284-96
pubmed: 25765327
Parkinsonism Relat Disord. 2021 Jul;88:68-75
pubmed: 34144230
Neurotherapeutics. 2020 Jul;17(3):1120-1141
pubmed: 31965550
J Neural Transm (Vienna). 2009 Jan;116(1):51-6
pubmed: 19034381
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Brain. 2017 Aug 1;140(8):2183-2192
pubmed: 28899020
Mov Disord. 2016 May;31(5):615-24
pubmed: 26880095
J Cereb Blood Flow Metab. 2012 Aug;32(8):1609-17
pubmed: 22569194
Magn Reson Med. 2009 Sep;62(3):717-30
pubmed: 19623619
Nat Commun. 2020 Apr 8;11(1):1739
pubmed: 32269213
Neurobiol Dis. 2019 Aug;128:59-66
pubmed: 30213733
Front Neural Circuits. 2015 Oct 31;9:68
pubmed: 26582977
J Gerontol A Biol Sci Med Sci. 2017 Nov 09;72(12):1656-1662
pubmed: 28472409
J Parkinsons Dis. 2021;11(3):1297-1308
pubmed: 34024781
Neurobiol Dis. 2020 Jun;139:104831
pubmed: 32145376
Cells. 2019 Aug 05;8(8):
pubmed: 31387313
Neurology. 2014 Jan 28;82(4):308-16
pubmed: 24363137
J Neurosci. 2020 Aug 19;40(34):6649-6659
pubmed: 32669353
Dementia. 1994 Sep-Oct;5(5):266-81
pubmed: 7951684
Front Aging Neurosci. 2014 Oct 21;6:249
pubmed: 25374538
Brain. 2015 Aug;138(Pt 8):2322-31
pubmed: 25981960
Proc Natl Acad Sci U S A. 1987 Aug;84(16):5976-80
pubmed: 3475716
Trends Neurosci. 1990 Jul;13(7):266-71
pubmed: 1695401
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Hum Brain Mapp. 1999;7(4):254-66
pubmed: 10408769
Neurology. 2010 Nov 9;75(19):1717-25
pubmed: 21060094
Mov Disord. 2020 Jul;35(7):1199-1207
pubmed: 32400071
Neuroscience. 2002;112(3):687-96
pubmed: 12074910
Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322
pubmed: 11545704
Sci Rep. 2018 Feb 13;8(1):2941
pubmed: 29440768
Neuron. 2017 Apr 5;94(1):7-18
pubmed: 28384477
Brain. 2018 May 1;141(5):1501-1516
pubmed: 29701787
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
AJNR Am J Neuroradiol. 2018 Mar;39(3):479-484
pubmed: 29419398
Brain Struct Funct. 2020 Jan;225(1):427-439
pubmed: 31894407
Brain Struct Funct. 2017 Aug;222(6):2547-2558
pubmed: 28283747
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Neuroimage. 2019 Nov 15;202:116138
pubmed: 31472250
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Parkinsonism Relat Disord. 2021 Oct;91:162-166
pubmed: 34628195
Dement Geriatr Cogn Disord. 2002;13(3):183-92
pubmed: 11893841
Curr Neurol Neurosci Rep. 2018 Oct 2;18(12):83
pubmed: 30280267
Lancet Neurol. 2016 Mar;15(3):249-58
pubmed: 26795874
Brain. 2016 Feb;139(Pt 2):495-508
pubmed: 26705348
Mov Disord. 2017 Oct;32(10):1457-1464
pubmed: 28714593
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):786-92
pubmed: 25224677